Welcome to our dedicated page for IDEX SEC filings (Ticker: IEX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Wading through IDEX’s three-segment disclosures can feel like stitching together separate engineering manuals written in accounting prose. Each filing blends fluid & metering margins with health-and-science acquisitions, while every transaction in the fire-and-safety unit sits in a different footnote. Locating warranty accruals, backlog swings or restructuring charges across a 250-page report demands hours you could spend making decisions.
Stock Titan fixes that. Our AI turns an IDEX annual report 10-K simplified into a dashboard that flags segment profit swings and M&A impacts in plain English. The latest IDEX quarterly earnings report 10-Q filing arrives with trend visuals and peer comparisons. Receive IDEX Form 4 insider transactions real-time; every IDEX executive stock transactions Form 4 is paired with contextual share-price data. Even the IDEX 8-K material events explained link directly to historical performance so you can gauge materiality fast.
Need governance details? Drill into the IDEX proxy statement executive compensation section to see how bonus targets line up with return on invested capital. Our platform also offers AI-powered summaries, real-time EDGAR alerts and side-by-side document comparisons—tools that make IDEX SEC filings explained simply more than a promise.
- IDEX insider trading Form 4 transactions
- IDEX earnings report filing analysis
- understanding IDEX SEC documents with AI
Stop scrolling endless PDFs. Get the intelligence you need—when you need it—and move from data collection to confident action in minutes.
IDEX Corporation announced that Sean M. Gillen will become Senior Vice President and Chief Financial Officer effective January 5, 2026, succeeding interim CFO Akhil Mahendra, who will return to his role as Vice President, Corporate Development. Gillen joins from AAR CORP., where he has been Senior Vice President and CFO since 2019, and previously held finance and investment banking roles at USG Corporation and Goldman Sachs.
Under an offer letter dated December 1, 2025, Gillen will receive a base salary of $625,000, target annual cash incentive equal to 85% of base salary starting with the 2026 program, and an annual equity grant targeted at $2,000,000. He will also receive a one-time restricted stock award valued at $3,000,000 that vests over three years and a cash sign-on bonus of $325,000, subject to repayment if he departs or is terminated for cause within 12 months. Severance protections include one year of base salary and target bonus if terminated without cause, increasing to two times those amounts if this occurs within 24 months after a change in control. IDEX also disclosed that Melissa S. Flores, Senior Vice President and Chief Human Resources Officer, will resign effective December 19, 2025 to pursue another opportunity.
IDEX Corporation (IEX) filed a Form 4 reporting an insider purchase. A company director bought 600 shares of common stock on 11/05/2025 at a weighted average price of $169.4112. Following the transaction, the director beneficially owns 6,351 shares, held directly.
The filing notes the trade was executed in multiple lots with prices ranging from $169.35 to $169.43. The weighted average reflects those individual executions, and the reporting person undertakes to provide the specific trade breakdown upon request.
IDEX Corporation (IEX) reported higher quarterly results. For the three months ended September 30, 2025, net sales were $878.7 million, up from $798.2 million, with operating income of $185.8 million versus $168.0 million. Diluted EPS was $1.70 compared with $1.57 a year ago.
Nine-month results were mixed: net sales rose to $2,558.4 million from $2,405.9 million, while net income attributable to IDEX was $354.9 million versus $381.8 million, and diluted EPS was $4.70 versus $5.02. Operating cash flow reached $470.9 million. The company repurchased $175.0 million of common stock year to date and declared a quarterly dividend of $0.71 per share.
Health & Science Technologies led growth, with Q3 revenue of $380.1 million (from $309.9 million), aided by acquisitions. IDEX completed the acquisition of Micro‑LAM for total consideration of $81.9 million and ended the quarter with cash and cash equivalents of $593.8 million and total borrowings of $1,911.8 million, including $310.6 million drawn on its revolving facility.
IDEX Corporation furnished an Item 2.02 Form 8‑K announcing quarterly results for the period ended September 30, 2025. The company issued a press release, provided as Exhibit 99.1, on October 29, 2025. This information is being furnished and is not deemed filed under the Exchange Act. The filing also lists Exhibit 104 for the cover page Inline XBRL tags.
Helmkamp Katrina L, identified as a director of IDEX Corporation (IEX), purchased 2,500 shares of common stock on 08/07/2025 at a weighted average price of $159.6104 per share, in multiple trades priced between $159.51 and $159.65. After the reported acquisition, the reporting person beneficially owns 13,200 shares directly.
The Form 4 shows no derivative transactions in Table II. A footnote states the transaction was executed in multiple trades and that the reporting person will provide detailed per-trade quantities and prices upon request.
FAQ
What is the current stock price of IDEX (IEX)?
What is the market cap of IDEX (IEX)?
